This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ATI-5923
Description: ATI-5923 is an oral anticoagulant based on warfarin. Like warfarin, it is a selective inhibitor of the vitamin K epoxide reductase enzyme, or a VKOR inhibitor. Four clotting factors are known to be controlled by the VKOR enzyme.
ATI-5923 is designed to be metabolized through the esterase pathway, eliminating metabolism through CYP450 (like warfarin) and avoiding drug-drug interactions. ATI-5923 may also have a flatter dose-response curve than warfarin, which could lead to lower variations in the anticoagulation status of patients.
Armetheon and Lee's Pharmaceutical Holdings
In September 2015, Armetheon announced that Armetheon and China Cardiovascular Focus, a subsidiary of Lees Pharmaceutical Holdings, have entered into an agreement to initiate advanced-stage clinical testing, manufacturing and commercialization of Armetheons investigational oral anticoagulant, tecarfarin, in the greater China market including Mainland China, Hong Kong, Macau, and Taiwan as well as Thailand.
Under the terms of the agreement, Lees Pharma gains exclusive rights to develop and commercialize tecarfarin in the greater China market and Thailand. Armetheon will receive an upfront cash payment in the form of a licensing fee along with an equity investment and development and sales milestone payments. In addition, Armetheon will receive royalties on future net sales. Lees Pharma will pay for the development, approval and commercialization of tecarfarin in the greater China market and Thailand.
Partners: Lee's Pharmaceutical Holdings Limited
Additional information available to subscribers only: